Pro Medicus Limited (PME.AX)
Healthcare · ASX · Australia
Fundamentals
Valuation and ratings
Pro Medicus Limited trades at AUD158.10, which is 45% above the AUD86.62 our discounted cash flow model puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 95 out of 100, which is a wide moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 82.5 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
PME.AX dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | AUD0.320 | 1 |
| 2025 | AUD0.550 | 2 |
| 2024 | AUD0.400 | 2 |
| 2023 | AUD0.300 | 2 |
| 2022 | AUD0.220 | 2 |
| 2021 | AUD0.150 | 2 |
| 2020 | AUD0.120 | 2 |
| 2019 | AUD0.105 | 3 |
| 2018 | AUD0.060 | 2 |
| 2017 | AUD0.040 | 2 |
| 2016 | AUD0.030 | 2 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
PME.AX earnings and analyst estimates
Recommendation mix, 15 analyst ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Pro Medicus Limited
Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software. It also provides Visage RIS, a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform for secure email and integration products. In addition, the company offers Visage Ease, a mobile application that provides users access to medical imaging results; and Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.
PME.AX passes 6 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Common questions
Is Pro Medicus Limited (PME.AX) undervalued?
Against our discounted cash flow estimate of AUD86.62, PME.AX at AUD158.10 is 45% above fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
What is PME.AX's P/E ratio?
PME.AX trades at 82.5 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Pro Medicus Limited (PME.AX) pay a dividend?
Yes. Pro Medicus Limited yields 0.34% at the current share price. It has paid AUD0.620 per share over the trailing twelve months. It has paid a dividend in each of the last 14 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
When does PME.AX report earnings next?
Pro Medicus Limited is scheduled to report on 18 Aug 2026. Companies move earnings dates, so read it as scheduled rather than certain.
The full research page for PME.AX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.